Related Experiment Video
Updated: Jun 25, 2026
06:17
A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
Galantamine inhibits beta-amyloid aggregation and cytotoxicity
Balpreet Matharu1, Gillian Gibson, Richard Parsons
1Neurodegeneration Unit, Basic Medical Sciences, St. George's University of London, Cranmer Terrace, Tooting, London SW17 0RE, UK.
Journal of the Neurological Sciences
|March 3, 2009
Summary
Galantamine effectively inhibits beta-amyloid peptide aggregation and reduces its toxicity in neuronal cells. This suggests potential disease-modifying effects beyond symptomatic treatment for conditions like Alzheimer's disease.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Beta-amyloid peptide (Abeta) aggregation and toxicity are implicated in neurodegenerative diseases.
- Galantamine is a known acetylcholinesterase inhibitor used for symptomatic treatment.
Purpose of the Study:
- To investigate the potential of galantamine to inhibit Abeta aggregation and toxicity.
- To explore if galantamine exhibits disease-modifying effects on Abeta pathology.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) to quantify Abeta aggregation.
- Electron microscopy to visualize Abeta fibril structure.
- MTT and lactate dehydrogenase assays to assess cell viability and cytotoxicity.
- Apoptosis assays on SH-SY5Y human neuroblastoma cells.
Main Results:
- Galantamine demonstrated concentration-dependent inhibition of Abeta 1-40 and Abeta 1-42 aggregation.
- Electron microscopy showed disordered and clumped Abeta fibrils in the presence of galantamine.
- Galantamine significantly reduced Abeta-induced cytotoxicity and apoptosis in neuronal cells.
Conclusions:
- Galantamine inhibits the aggregation and toxicity of beta-amyloid peptide.
- These findings suggest galantamine may possess disease-modifying properties, potentially impacting Abeta aggregation and toxicity pathways.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...